Compelling evidence indicates that METTL3 is negatively correlated with the efficacy of anti-PD-1 therapy in various tumor cells, including CRC, melanoma, and NSCLC (28, 30, 35). This evidence concerns the gene METTL3 and non-small cell lung carcinoma.